AstraZeneca and Daiichi-Sankyo invite OSCO members to attend a live broadcast exploring newly approved ENHERTU® therapy for adult patients with unresectable or metastatic HER2-positive breast cancer.

OSCO members are invited to join your peers for an exciting live broadcast event on February 5 at Vast Restaurant featuring an expert-led discussion presented by Hope Rugo, MD. exploring newly approved ENHERTU® therapy for adult patients with unresectable or metastatic HER2-positive breast cancer.  Contact Tara O’Mahony for more information and to RSVP at [email protected]



No comments have been posted yet.